Video

Dr. Kaufman hails autologous muscle-derived cells as "transformational" SUI treatment

Author(s):

Urology Times staff

“This technology is truly a transformational opportunity for urology,” says Melissa R. Kaufman, MD, PhD, FACS.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

      In this video, Melissa R. Kaufman, MD, PhD, FACS, discusses autologous muscle derived cells for urinary sphincter repair (AMDC-USR) and how this technology is designed to treat stress urinary incontinence (SUI) in female patients. Kaufman is a professor of urology and chief of the division of reconstructive urology and pelvic health at Vanderbilt University, Nashville, Tennessee.

      Newsletter

      Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

      Subscribe Now!
      Related Videos
      Roger Dmochowski, MD, on quality-of-life outcomes with the Revi System
      Roger Dmochowski, MD, on quality-of-life outcomes with the Revi System
      Amir Patel, MD, on onabotulinumtoxinA injection at the time of HoLEP
      Amir Patel, MD, on onabotulinumtoxinA injection at the time of HoLEP
      Bashir Al Hussein Al Awamlh, MD, MPH, answers a question during a Zoom video interview
      Data link incontinence severity to post-radical prostatectomy care
      Shot of a doctor showing a patient some information on a digital tablet | Image Credit | © bongkarn - stock.adobe.com
      OnabotA for OAB: Enhancing comfort and ensuring adherence
      Roger Dmochowski, MD, on real-world persistence with vibegron for OAB
      Roger Dmochowski, MD, on real-world persistence with vibegron for OAB
      Considerations for patient follow-up after onabotA administration
      Considerations for patient follow-up after onabotA administration
      Administering onabotA: Improving patient comfort and easing anxiety
      Administering onabotA: Improving patient comfort and easing anxiety
      Sam Chang, MD, shares updated data on nogapendekin alfa inbakicept in NMIBC
      Sam Chang, MD, shares updated data on nogapendekin alfa inbakicept in NMIBC
      Shot of a doctor showing a patient some information on a digital tablet | Image Credit: © - bongkarn - stock.adobe.com
      Experts discuss expanding use of vibegron for OAB
      Ekene Enemchukwu, MD, on guideline-associated trends in OAB therapy use
      Ekene Enemchukwu, MD, on guideline-associated trends in OAB therapy use
      Related Content
      Howard B. Goldman, MD, FACS
      June 23rd 2025

      The future of OAB treatment: Emerging nerve targets and AI may guide therapy

      Howard B. Goldman, MD
      Howard B. Goldman, MD, FACS, discusses innovations such as tibial nerve stimulation devices, pudendal nerve targeting, and alternative stimulation frequencies.
      Speaking of Urology: Melissa Kaufman, MD, on AUA’s new guideline on genitourinary syndrome of menopause
      April 28th 2025

      Speaking of Urology: Melissa Kaufman, MD, on AUA’s new guideline on genitourinary syndrome of menopause

      Melissa Kaufman, MD, PhD, FACS
      In this episode, guideline chair Melissa Kaufman, MD, PhD, FACS, highlights key points from the new AUA GSM guideline and illustrates its impact for clinical management of this condition.
      From prep to follow-up: Key considerations for administering onabotulinumtoxinA
      June 13th 2025

      From prep to follow-up: Key considerations for administering onabotulinumtoxinA

      Benjamin M. Brucker, MD Hannah Clarke
      Benjamin M. Brucker, MD, discusses best practices for the onabotulinumtoxinA procedure, spanning all phases of treatment—before, during, and after administration.
      Dr. Dobberfuhl discusses novel onabotulinumtoxinA treatment for refractory OAB
      March 21st 2022

      Dr. Dobberfuhl discusses novel onabotulinumtoxinA treatment for refractory OAB

      Urology Times staff
      “This technique is feasible, it is very well tolerated, and there’s not much of a complication rate, so it appears to be very safe,” says Amy D. Dobberfuhl, MD, MS.
      Published data support safety, efficacy of vaginal insert for SUI
      May 14th 2025

      Published data support safety, efficacy of vaginal insert for SUI

      Hannah Clarke
      Yōni.Fit bladder support was granted FDA 510(k) clearance in May 2024.
      Artificial urinary sphincter for SUI shows safety, efficacy in prospective study
      May 9th 2025

      Artificial urinary sphincter for SUI shows safety, efficacy in prospective study

      Melissa Kaufman, MD, PhD, FACS Hannah Clarke
      "This trial will be the benchmark for research reporting in the future," says Melissa R. Kaufman, MD, PhD, FACS.
      © 2025 MJH Life Sciences

      All rights reserved.